Dengue virus: Molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria

Scott B. Halstead; Franz X. Heinz; A. D.T. Barrett; John T. Roehrig

doi:10.1016/j.vaccine.2004.03.069

Dengue virus: Molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria

Scott B. Halstead, Franz X. Heinz, A. D.T. Barrett, John T. Roehrig

Pathology

Research output: Contribution to journal › Article › peer-review

67 Scopus citations

Abstract

Multivalent dengue vaccines now in late stage development pose unique vaccine safety challenges in that primary or secondary vaccine failures might place vaccines at risk to antibody-dependent enhanced (ADE) wild-type dengue infections. This conference was organized to address this unique vaccine safety issue. New data were presented on the structure of dengue and other flaviviruses, the cellular receptors of dengue virus for biologically relevant cells, dengue viral cell entry mechanisms and mechanisms underlying in vivo protection, neutralization and enhancement of dengue virus infection. It was concluded that a targeted research program should aim to develop an in vitro test to characterize persons immunized with dengue vaccines as completely or partially protected. Achievement of this aim will require a better understanding of the basic mechanisms by which dengue viruses recognize, attach, enter and infect relevant human cells and how antibodies protect against dengue infections.

Original language	English (US)
Pages (from-to)	849-856
Number of pages	8
Journal	Vaccine
Volume	23
Issue number	7
DOIs	https://doi.org/10.1016/j.vaccine.2004.03.069
State	Published - Jan 4 2005

Keywords

Antibodies
Dengue
Vaccine
Viral structure

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2004.03.069

Cite this

@article{6c1fdd30019645c08630dd21c61267d4,

title = "Dengue virus: Molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria",

abstract = "Multivalent dengue vaccines now in late stage development pose unique vaccine safety challenges in that primary or secondary vaccine failures might place vaccines at risk to antibody-dependent enhanced (ADE) wild-type dengue infections. This conference was organized to address this unique vaccine safety issue. New data were presented on the structure of dengue and other flaviviruses, the cellular receptors of dengue virus for biologically relevant cells, dengue viral cell entry mechanisms and mechanisms underlying in vivo protection, neutralization and enhancement of dengue virus infection. It was concluded that a targeted research program should aim to develop an in vitro test to characterize persons immunized with dengue vaccines as completely or partially protected. Achievement of this aim will require a better understanding of the basic mechanisms by which dengue viruses recognize, attach, enter and infect relevant human cells and how antibodies protect against dengue infections.",

keywords = "Antibodies, Dengue, Vaccine, Viral structure",

author = "Halstead, {Scott B.} and Heinz, {Franz X.} and Barrett, {A. D.T.} and Roehrig, {John T.}",

note = "Funding Information: New insights derived from cryo-electron microscopic studies on the dengue virion, [25] the crystallization of the dengue 2 envelope protein, [26,27] structural studies on immature dengue particles [22] and studies on flavivirus fusion processes are examples of the foundational studies needed to achieve a better understanding of the receptor and entry pathways mediating dengue infection in humans. Critically missing in receptor research is the identity of the specific cells that support dengue infections in human beings. The PDVI announced that studies on topics discussed at this meeting will be funded in a targeted and networked research program with a goal of identifying protective and enhancing antibody responses raised by dengue viral infections. This outcome could result in a laboratory test that reliably identifies vaccine-induced immunity as protective/non-protective or contribute to a rational basis for improving the design of dengue vaccines. The PDVI received major funding from the Bill and Melinda Gates Foundation in 2003 permitting the first PDVI research grants to be awarded in mid-2004.",

year = "2005",

month = jan,

day = "4",

doi = "10.1016/j.vaccine.2004.03.069",

language = "English (US)",

volume = "23",

pages = "849--856",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd",

number = "7",

}

TY - JOUR

T1 - Dengue virus

T2 - Molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria

AU - Halstead, Scott B.

AU - Heinz, Franz X.

AU - Barrett, A. D.T.

AU - Roehrig, John T.

N1 - Funding Information: New insights derived from cryo-electron microscopic studies on the dengue virion, [25] the crystallization of the dengue 2 envelope protein, [26,27] structural studies on immature dengue particles [22] and studies on flavivirus fusion processes are examples of the foundational studies needed to achieve a better understanding of the receptor and entry pathways mediating dengue infection in humans. Critically missing in receptor research is the identity of the specific cells that support dengue infections in human beings. The PDVI announced that studies on topics discussed at this meeting will be funded in a targeted and networked research program with a goal of identifying protective and enhancing antibody responses raised by dengue viral infections. This outcome could result in a laboratory test that reliably identifies vaccine-induced immunity as protective/non-protective or contribute to a rational basis for improving the design of dengue vaccines. The PDVI received major funding from the Bill and Melinda Gates Foundation in 2003 permitting the first PDVI research grants to be awarded in mid-2004.

PY - 2005/1/4

Y1 - 2005/1/4

N2 - Multivalent dengue vaccines now in late stage development pose unique vaccine safety challenges in that primary or secondary vaccine failures might place vaccines at risk to antibody-dependent enhanced (ADE) wild-type dengue infections. This conference was organized to address this unique vaccine safety issue. New data were presented on the structure of dengue and other flaviviruses, the cellular receptors of dengue virus for biologically relevant cells, dengue viral cell entry mechanisms and mechanisms underlying in vivo protection, neutralization and enhancement of dengue virus infection. It was concluded that a targeted research program should aim to develop an in vitro test to characterize persons immunized with dengue vaccines as completely or partially protected. Achievement of this aim will require a better understanding of the basic mechanisms by which dengue viruses recognize, attach, enter and infect relevant human cells and how antibodies protect against dengue infections.

AB - Multivalent dengue vaccines now in late stage development pose unique vaccine safety challenges in that primary or secondary vaccine failures might place vaccines at risk to antibody-dependent enhanced (ADE) wild-type dengue infections. This conference was organized to address this unique vaccine safety issue. New data were presented on the structure of dengue and other flaviviruses, the cellular receptors of dengue virus for biologically relevant cells, dengue viral cell entry mechanisms and mechanisms underlying in vivo protection, neutralization and enhancement of dengue virus infection. It was concluded that a targeted research program should aim to develop an in vitro test to characterize persons immunized with dengue vaccines as completely or partially protected. Achievement of this aim will require a better understanding of the basic mechanisms by which dengue viruses recognize, attach, enter and infect relevant human cells and how antibodies protect against dengue infections.

KW - Antibodies

KW - Dengue

KW - Vaccine

KW - Viral structure

UR - http://www.scopus.com/inward/record.url?scp=10444256421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10444256421&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2004.03.069

DO - 10.1016/j.vaccine.2004.03.069

M3 - Article

C2 - 15603884

AN - SCOPUS:10444256421

SN - 0264-410X

VL - 23

SP - 849

EP - 856

JO - Vaccine

JF - Vaccine

IS - 7

ER -

Dengue virus: Molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this